This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. July 29, ...
For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website is to provide initial guidance only and it does ...
The FDA has notified healthcare professionals of an update to a previous alert from September 2007 addressing the interaction of ceftriaxone with calcium-containing products. At the FDA’s request, ...
Attenuation of Ethanol Withdrawal by Ceftriaxone-Induced Upregulation of Glutamate Transporter EAAT2
Alcohol withdrawal syndrome (AWS) is a potentially fatal outcome of severe alcohol dependence that presents a significant challenge to treatment. Although AWS is thought to be driven by a ...
Lupin Pharmaceuticals, Inc. is voluntarily recalling 5 lots of Ceftriaxone for Injection, USP, 250mg, 10 lots of Ceftriaxone for Injection, USP, 500mg, 24 lots of Ceftriaxone for Injection, USP, 1g ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback